Skip to content
MARKETS / NASDAQ / IVVD
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Invivyd, Inc. IVVD

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$53.4M
▲ 110.5% YoY
$-52.5M
$-58.3M
In brief

What this company does

The company aims to develop mAbs that could be used in prevention or treatment of serious viral infectious diseases, starting with COVID-19 and expanding into other high-need indications, such as respiratory syncytial virus and measles. As of February 1, 2026, the company had 122 employees, all of which were full-time employees. Approximately 16 of the company's employees have Ph.D. or M.D. degrees and 35 of its employees are engaged in research and development activities. The company operates as a hybrid company with employees working at its corporate headquarters in New Haven, Connecticut, its laboratory in Newton, Massachusetts and remotely.

Written from the business description in Invivyd, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 5 March 2026. Every sentence was checked against that document before publication.

Growth
USD 53.4M
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2025 · Revenue 53.4 · Net income -52.5
20M40M-80M-160M202020212022202320242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−98 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -104.0% · Net -98.2%
-200%-400%-600%202020212022202320242025
ROE
FY2025 · ROE -34.0%
-50%-100%202020212022202320242025

Each USD of equity lost 34 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -58.3
-80M-160M202020212022202320242025
Net buybacks $M Dividends $M
FY2024 · Dividends — · Net buybacks -0.2
-200M2021202220232024

Total assetsUSD 276.9M
EquityUSD 241.5M
CashUSD 226.7M
Current ratio7.24×

Equity funds 87% of total assets.

The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020
Revenue $B0.10.00.0···
Operating income $B−0.1−0.2−0.2−0.2−0.2·
EBITDA $B··−0.2−0.2−0.2·
Income tax $B0.00.00.00.00.0·
Net income $B−0.1−0.2−0.2−0.2−0.2−0.0
Free cash flow $B−0.1−0.2−0.2−0.2−0.2·
EPS, diluted $−0.30−1.43−1.81−2.23−5.32·
Dividend / sh $······
Payout %······
ROE %−34.0−138.7−74.5−52.8−92.0·
Shares out B0.280.120.110.110.110.01

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 23 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 53 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2020

Share this section

Download image